Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alprostadil liposomal - CSPC ZhongQi Pharmaceutical Technology

Next Previous
Drug Profile

Alprostadil liposomal - CSPC ZhongQi Pharmaceutical Technology

Alternative Names: Alprostadil liposome for injection

Latest Information Update: 10 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Class Erectile dysfunction therapies; Monounsaturated fatty acids; Muscle relaxants; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute kidney injury
  • No development reported Arteriosclerosis obliterans

Most Recent Events

  • 20 Oct 2022 Phase-II clinical trials in Acute kidney injury (Prevention, In adults, In the elderly) in China (IV) (NCT05475717)
  • 27 Jul 2022 CSPC ZhongQi Pharmaceutical Technology plans a phase II trial for Acute kidney injury (in patients undergoing percutaneous coronary intervention) (Prevention, In adults, In the elderly) in China (Injection) (NCT05475717)
  • 26 Jul 2022 No development reported - Phase-II for Arteriosclerosis obliterans in China (IV) (NCT04197323)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top